[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-mucus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-mucus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100612012","smartphone-vs-manual-interpretation-of-biomarkers-for-ovulation-and-luteal-phase-detection-smom-study-100612012",false,"NCT07248046","Smartphone vs Manual Interpretation of Biomarkers for Ovulation and Luteal Phase Detection (SMOM Study)","Comparing Cervical Mucus, PDG, LH, and Basal Body Temperature Combinations for Ovulation and Luteal Phase Identification Using the Premom Smartphone App Versus User-Read Test Results: A Prospective Observational Study","SMOM","Inclusion Criteria:\n\n* Female, aged 16 to 45\n* Natural menstrual cycles equal or less than 35 days\n* Off hormonal contraception for more than 3 months\n* Current user of the Premom App\n* Willing to track cervical mucus, LH, PDG, and BBT for 3 full cycles\n* Lives within 50 km of study site in the Ottawa region\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current hormonal therapy or contraception\n* Known anovulatory disorders, e.g., Polycystic Ovary Syndrome, hypothalamic amenorrhea.\n* Very irregular or absent cycles\n* Not using the Premom App\n* Unable or unwilling to complete tracking or provide consent",true,"FEMALE","16 Years","45 Years",{"count":22,"type":23},30,"ESTIMATED","OBSERVATIONAL","This study will compare different combinations of fertility signs (cervical mucus (CM), luteinizing hormone \\[LH\\], pregnanediol glucuronide \\[PDG\\], and basal body temperature \\[BBT\\]) to determine which are most reliable for identifying ovulation and luteal phase length. Thirty existing Premom App users will track daily observations for three menstrual cycles. Participants will record mucus, perform urine tests, upload test strip photos to the Premom App, and measure BBT. Both participant readings and AI-assisted app readings will be analyzed. The main goal is to find which marker pairings give the most accurate picture of ovulation timing and luteal phase length. Secondary goals include understanding ease of use, the number of tests required, and whether the app improves accuracy.",[27,28,29,30,31,32,33,34,35],"Fertility","Mobile Applications","Artifical Intelligence","Cervical Mucus","Body Temperature","Luteinizing Hormone (LH)","Ovulation","Menstrual Cycle","Progesterone",[33,37,34,27,30,38,39,35,40,41,42,28,43,44,45,46,47,48,49,50],"Luteal Phase","Luteinizing Hormone","Pregnanediol Glucuronide","Basal Body Temperature","Female Reproductive Physiology","Fertility Awareness-Based Methods","Smartphone App","Artificial Intelligence","Self-Testing","Home Diagnostic Tests","Observational Study","Prospective Studies","Digital Health","Women's Health","RECRUITING","2026-01-10",{"date":54,"type":55},"2026-01-13","ACTUAL",{"date":57,"type":23},"2026-01-15",{"date":59,"type":23},"2026-11-15",{"name":61,"class":62},"Bruyère Health Research Institute.","OTHER",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":17,"sex":18,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":63},"100601496","phase-4-insights-in-endocervical-mucus-secretion-100601496","NCT07111247","Insights in Endocervical Mucus Secretion","Inclusion Criteria:\n\n* Normal menstrual cycles of 25-35 days in length for at least the previous 3 cycles\n* BMI \\>18 and \\\u003C35\n* Serum p4 \\>= 3 ng\u002Fml on single sample collected between days 18-25 of self-reported menstrual cycle\n* Flexible schedule allowing blood draws on less than 48 hour notice\n* In good general health\n* Commit to using non-hormonal contraceptive methods without spermicide during study period except those prescribed in the experimental protocol\n* No objections to taking study drugs\n* No objections to refraining from intercourse the night before any sampling and willing to use condoms during vaginal intercourse\n\nExclusion Criteria:\n\n* Oral contraceptive use or other hormone supplement within the preceding 2 months\n* Current cervical infection\n* Evidence of abnormal cervical cytology\n* Use of any IUD for contraception\n* Long-acting hormonal contraceptive use in the past 12 months (e.g., Depo-Provera)\n* Contraindications to study drugs\n* Current or past pregnancy within the previous 6 months or currently trying to conceive\n* Desiring to conceive in the next 8 months\n* Breastfeeding in the past 2 months\n* Diagnosed diabetes or metabolic syndrome\n* Diagnosed Polycystic Ovary Syndrome\n* History of, or self-reported, substance abuse\n* Smoker\n* Previous infertility treatment excluding male factor issues\n* Use of an investigational drug within the past 2 months\n* History of excisional or ablative treatment procedure on cervix (i.e., LEEP, Cryotherapy, Cold Knife Cone)\n* Current treatment for a vaginal infection such as bacterial vaginosis\n* History of venous thromboembolism (VTE) or inherited thrombophilias","21 Years","40 Years",{"count":73,"type":23},15,"INTERVENTIONAL",[76],"PHASE4","Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.",[30],"2026-01-06",{"date":81,"type":55},"2026-01-08",{"date":83,"type":55},"2026-01-02",{"date":85,"type":23},"2027-08",{"name":87,"class":62},"Oregon Health and Science University"]